Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative chemoradiation with capecitabine and cetuximab in operable T3–T4 rectal cancer
2005-003740-62Phase 2Completed
- Sponsor
- Austrian Breast and Colorectal Cancer Study Group
- Start
- Sep 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and cetuximab in rectal cancer, sponsored by Austrian Breast and Colorectal Cancer Study Group. Primary endpoints: Feasibility of preoperative cetuximab + capecitabine chemoradiation and Tolerance and safety of preoperative combination therapy. Started Sep 2005; status: completed.
02
Drugs
capecitabinecetuximab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2005-003740-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003740-62.